FDA-approved Alzheimer's drug lecanemab could prevent free-floating amyloid beta fibrils from damaging the brain

Researchers described the structure of a special type of amyloid beta plaque protein associated with Alzheimer's disease (AD) progression. Scientists showed the small aggregates of the amyloid beta protein could float through the brain tissue fluid, reaching many brain regions and disrupting local neuron functioning. The research also provided evidence that a newly approved AD treatment could neutralize these small, diffusible aggregates.

from All Top News -- ScienceDaily https://ift.tt/PzyHUlb